Neogen Capex To Depreciation vs Free Cash Flow Yield Analysis
NEOG Stock | USD 11.64 0.49 4.04% |
Neogen financial indicator trend analysis is infinitely more than just investigating Neogen recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neogen is a good investment. Please check the relationship between Neogen Capex To Depreciation and its Free Cash Flow Yield accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.
Capex To Depreciation vs Free Cash Flow Yield
Capex To Depreciation vs Free Cash Flow Yield Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neogen Capex To Depreciation account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak relationship.
The correlation between Neogen's Capex To Depreciation and Free Cash Flow Yield is 0.36. Overlapping area represents the amount of variation of Capex To Depreciation that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Neogen, assuming nothing else is changed. The correlation between historical values of Neogen's Capex To Depreciation and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Depreciation of Neogen are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Capex To Depreciation i.e., Neogen's Capex To Depreciation and Free Cash Flow Yield go up and down completely randomly.
Correlation Coefficient | 0.36 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Most indicators from Neogen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neogen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.At this time, Neogen's Enterprise Value is most likely to increase significantly in the upcoming years.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 243.0M | 406.0M | 463.9M | 487.1M | Total Revenue | 527.2M | 822.4M | 924.2M | 970.4M |
Neogen fundamental ratios Correlations
Click cells to compare fundamentals
Neogen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neogen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 797.2M | 920.2M | 992.9M | 4.6B | 4.5B | 4.8B | |
Other Current Liab | 22.8M | 26.6M | 35.6M | 57.2M | 48.6M | 51.1M | |
Total Current Liabilities | 48.5M | 53.6M | 77.8M | 145.5M | 154.3M | 162.0M | |
Total Stockholder Equity | 725.2M | 840.4M | 887.4M | 3.1B | 3.1B | 3.3B | |
Property Plant And Equipment Net | 78.7M | 100.5M | 110.6M | 198.7M | 291.9M | 306.5M | |
Net Debt | (342.6M) | (379.8M) | 605.6M | 736.8M | 735.6M | 772.4M | |
Retained Earnings | 478.7M | 539.6M | 587.9M | 565.0M | 555.6M | 583.4M | |
Cash | 343.7M | 381.1M | 381.1M | 163.2M | 170.6M | 179.1M | |
Non Current Assets Total | 259.8M | 328.7M | 366.1M | 4.0B | 4.0B | 4.2B | |
Non Currrent Assets Other | 2.2M | 2.0M | 2.2M | 15.2M | 20.2M | 15.7M | |
Cash And Short Term Investments | 343.7M | 381.1M | 381.1M | 245.6M | 170.9M | 179.5M | |
Net Receivables | 84.7M | 91.8M | 99.7M | 153.3M | 173.0M | 181.7M | |
Common Stock Shares Outstanding | 105.7M | 107.1M | 108.0M | 188.9M | 216.5M | 227.3M | |
Liabilities And Stockholders Equity | 797.2M | 920.2M | 992.9M | 4.6B | 4.5B | 4.8B | |
Non Current Liabilities Total | 23.5M | 26.2M | 27.7M | 1.3B | 1.3B | 1.3B | |
Inventory | 95.1M | 100.7M | 122.3M | 133.8M | 189.3M | 198.7M | |
Other Current Assets | 14.0M | 35.7M | 47.5M | 53.3M | 56.0M | 58.8M | |
Other Stockholder Equity | 257.7M | 295.0M | 310.0M | 2.6B | 2.6B | 2.7B | |
Total Liab | 72.0M | 79.8M | 105.6M | 1.4B | 1.4B | 1.5B | |
Property Plant And Equipment Gross | 80.6M | 102.9M | 215.5M | 318.9M | 432.2M | 453.8M | |
Total Current Assets | 537.4M | 591.5M | 626.8M | 585.9M | 589.2M | 618.7M | |
Accumulated Other Comprehensive Income | (19.7M) | (11.4M) | (27.8M) | (33.3M) | (30.0M) | (28.5M) | |
Intangible Assets | 66.6M | 92.3M | 107.5M | 1.6B | 1.5B | 1.6B | |
Accounts Payable | 25.7M | 23.9M | 34.6M | 76.7M | 83.1M | 87.2M | |
Common Stock Total Equity | 8.5M | 17.2M | 17.2M | 34.6M | 39.8M | 41.8M | |
Short Term Investments | 277.4M | 305.5M | 336.6M | 82.3M | 325K | 308.8K | |
Common Stock | 8.5M | 17.2M | 17.2M | 34.6M | 34.7M | 32.9M | |
Other Liab | 22.6M | 26.2M | 27.7M | 375.7M | 432.1M | 453.7M | |
Other Assets | 2.2M | 2.0M | 4.8B | 15.2M | 1.0 | 0.95 | |
Good Will | 181.1M | 228.3M | 255.5M | 3.8B | 2.1B | 2.2B | |
Property Plant Equipment | 78.7M | 100.5M | 110.6M | 198.7M | 228.6M | 240.0M | |
Net Tangible Assets | 599.6M | 612.1M | 887.4M | 3.1B | 3.6B | 3.8B | |
Retained Earnings Total Equity | 478.7M | 539.6M | 587.9M | 565.0M | 649.8M | 382.8M |
Currently Active Assets on Macroaxis
When determining whether Neogen is a strong investment it is important to analyze Neogen's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neogen's future performance. For an informed investment choice regarding Neogen Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neogen. If investors know Neogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share (0.11) | Revenue Per Share 4.212 | Quarterly Revenue Growth (0.05) | Return On Assets 0.0085 |
The market value of Neogen is measured differently than its book value, which is the value of Neogen that is recorded on the company's balance sheet. Investors also form their own opinion of Neogen's value that differs from its market value or its book value, called intrinsic value, which is Neogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neogen's market value can be influenced by many factors that don't directly affect Neogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.